Bio-Techne Earnings Reports

Bio-Techne reported a 1% decrease in both reported and organic revenue for the first quarter of fiscal 2026, reaching $286.6 million. GAAP EPS increased to $0.24 from $0.21 in the prior year, while adjusted EPS remained stable at $0.42. The company completed the divestiture of its Exosome Diagnostics business and saw an increase in adjusted operating margin to 29.9% due to productivity and cost containment initiatives.

Bio-Techne saw 4% reported revenue growth in Q4, led by strength in Protein Sciences. However, the quarter resulted in a GAAP net loss due to an $83M impairment related to Exosome Diagnostics. Adjusted EPS rose to $0.53.

Bio-Techne delivered solid Q3 2025 results with 6% organic revenue growth and strong performance in its Protein Sciences segment. Adjusted EPS rose to $0.56, and the company achieved a 34.9% adjusted operating margin, supported by improved profitability and operational leverage.

Bio-Techne reported a 9% increase in second-quarter revenue to $297.0 million, driven by strong organic growth in both the Protein Sciences and Diagnostics & Spatial Biology segments. GAAP EPS increased to $0.22, and adjusted EPS rose to $0.42. The company also highlighted improved biopharma end-market conditions and a focus on profitability, resulting in a 30.1% adjusted operating margin.

Bio-Techne reported a 5% increase in revenue to $289.5 million, with organic revenue growth of 4%. GAAP EPS was $0.21, while adjusted EPS increased to $0.42. The Diagnostics & Spatial Biology segment drove growth with a 14% organic increase.

Bio-Techne reported a 2% increase in net sales for the fourth quarter of fiscal year 2024, reaching $306.1 million. GAAP EPS was $0.25, while adjusted EPS was $0.49. The Diagnostics & Genomics segment showed strong growth, with a 15% increase in net sales.

Bio-Techne reported a 3% increase in revenue to $303.4 million, with organic revenue growth of 2%. GAAP EPS was $0.31, while adjusted EPS reached $0.48. The Diagnostics & Genomics segment demonstrated strong growth, with 10% organic segment growth. Cash flow from operations increased by 31% to $223.5 million.

Bio-Techne reported flat revenue growth in the second quarter of fiscal year 2024, with organic revenue declining by 2%. GAAP EPS was $0.17, while adjusted EPS was $0.40. The company faced headwinds from BioPharma macroeconomic conditions but saw strength in the academic end market and growth in instrument consumables.

Bio-Techne reported a 3% increase in first-quarter revenue to $276.9 million, with organic revenue growth of 2%. GAAP EPS was $0.31, while adjusted EPS was $0.41. The company highlighted strong performance in EMEA and continued growth in key product lines.

Bio-Techne reported a 5% increase in organic revenue for Q4 2023, reaching $301.3 million. The company's Diagnostics and Genomics segment saw a 10% organic growth, driven by strong commercial execution. Strategic growth platforms like ExoDx prostate test and GMP proteins delivered record performance with revenue growth of 68% and 58%, respectively. Bio-Techne also finalized the acquisition of Lunaphore, enhancing its spatial biology franchise.

Bio-Techne reported a 1% increase in revenue to $271.6 million, with organic growth of 4%. GAAP EPS was $0.31, while adjusted EPS was $0.47. The company faced challenges from slow Biotech funding and COVID-19 impacts in China but saw strength in the US consumable business and Cell Therapy portfolio.

Bio-Techne Corporation reported a 5% increase in net sales to $269.7 million for the first quarter of fiscal year 2023. The Diagnostics and Genomics segment showed significant organic growth, offsetting challenges in the Protein Sciences segment. GAAP EPS was $2.21, while adjusted EPS was $1.78.

Bio-Techne reported a 19% increase in net sales, reaching $290.4 million, with organic growth of 17%. GAAP EPS was $1.48, and adjusted EPS was $2.14. The company highlighted strong performance in both Protein Sciences and Diagnostics and Genomics segments, and announced an exclusive agreement with Thermo Fisher Scientific.

Bio-Techne reported a strong second quarter in fiscal year 2022, with a 20% increase in net sales to $269.3 million and organic revenue growth of 17%. The company's adjusted EPS increased to $1.88, and adjusted operating income rose by 18% to $102.8 million. The Protein Sciences segment demonstrated sustained operational excellence, achieving 19% organic growth.

Bio-Techne reported a strong start to fiscal year 2022, with a 26% increase in net sales to $257.7 million and organic revenue growth of 21%. GAAP EPS was $1.69, up from $0.83 in the same quarter last year, and adjusted EPS increased to $1.83 from $1.43. The company experienced broad strength across its portfolio, particularly in the Protein Sciences segment, and made significant progress in its Cell and Gene Therapy initiatives.

Bio-Techne reported a strong fourth quarter with a 39% increase in organic revenue and an adjusted operating margin of 38.5%. The company's Protein Sciences and Diagnostics and Genomics segments achieved record organic growth. Management sees continued momentum as they penetrate the life science markets.

Bio-Techne reported a strong third quarter in fiscal year 2021, with a 25% increase in net sales to $243.6 million and organic growth of 22%. The company's adjusted operating margin improved to 40.1%, and adjusted EPS increased by 29% to $1.79.

Bio-Techne reported a 21% increase in net sales to $224.3 million, with organic growth of 19%. GAAP EPS was $1.15, while adjusted EPS reached a record $1.62. The adjusted operating margin improved to 38.7%.

Bio-Techne reported a strong first quarter for fiscal year 2021, with organic revenue growth of 10% and adjusted EPS increasing by 35%. The company benefited from the reopening of customer sites and demand for its life science tools and diagnostic reagents.

Bio-Techne reported a decrease in fourth-quarter organic revenue by 8% to $175.8 million. GAAP EPS was $1.48, while adjusted EPS was $1.00. The company finished the fiscal year with 4% organic growth despite market disruptions.

Bio-Techne reported a 5% increase in net sales to $194.7 million for Q3 2020, with organic growth of 6%. GAAP EPS decreased to $0.92, while adjusted EPS increased to $1.39. The company highlighted its role in combating COVID-19 and maintained a strong financial position.

Bio-Techne reported a solid second quarter with a 6% increase in organic revenue, reaching $184.9 million. GAAP EPS was $3.02, driven by a gain on the ChemoCentryx investment, while adjusted EPS increased by 2% to $1.08. The Diagnostics and Genomics segment showed strong organic growth of 12%.